Evidence map›Paper›PMID 41866403›Full record

ArticleCell death discovery2026

ADA2-deficient cells exhibit increased levels of cell death and metabolic disturbances.

Lisa Ehlers, Marjon Wouters, Bethany Pillay, Selket Delafontaine, Giorgia Bucciol, Marco Baggio, Mariia Dzhus, Anneleen Hombrouck, Alexandra Damerau, Lien De Somer and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Lisa EhlersDepartment of Microbiology, Immunology and Transplantation, Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0001-8737-001X
Marjon WoutersDepartment of Microbiology, Immunology and Transplantation, Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium.
Bethany PillayDepartment of Microbiology, Immunology and Transplantation, Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0001-7964-544X
Selket DelafontaineDepartment of Microbiology, Immunology and Transplantation, Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium.
Giorgia BucciolDepartment of Microbiology, Immunology and Transplantation, Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium.
Marco BaggioDepartment of Microbiology, Immunology and Transplantation, Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium.
Mariia DzhusDepartment of Microbiology, Immunology and Transplantation, Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium.
Anneleen HombrouckDepartment of Microbiology, Immunology and Transplantation, Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium.
Alexandra DamerauDeutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Association, Berlin, Germany.
Lien De SomerDepartment of Pediatrics, University Hospitals Leuven, Leuven, Belgium.
Rik SchrijversDepartment of Microbiology, Immunology and Transplantation, Allergy and Clinical immunology Research group, KU Leuven, Leuven, Belgium.
Steven VanderschuerenDepartment of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium.
Maarten JacquemynKU Leuven Department of Microbiology, Immunology and Transplantation, Molecular Genetics and Therapeutics in Virology and Oncology Research Group, Rega Institute for Medical Research, Leuven, Belgium.ORCID http://orcid.org/0000-0003-2626-4189
Tilmann KallinichDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Dirk DaelemansKU Leuven Department of Microbiology, Immunology and Transplantation, Molecular Genetics and Therapeutics in Virology and Oncology Research Group, Rega Institute for Medical Research, Leuven, Belgium.
Bart GhesquièreDepartment of Cellular and Molecular Medicine, Laboratory of Applied Mass Spectrometry, KU Leuven, Leuven, Belgium.
Patrizia AgostinisCell Death Research & Therapy (CDRT) Lab, Department of Cellular & Molecular Medicine, Center for Cancer Biology, VIB-KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0003-1314-2115
Leen MoensDepartment of Microbiology, Immunology and Transplantation, Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium.
Isabelle MeytsDepartment of Microbiology, Immunology and Transplantation, Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium. isabelle.meyts@uzleuven.be.ORCID http://orcid.org/0000-0003-1214-0302

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 530960394EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 948959Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 11E0123NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 11F4421NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 1805523NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G0A3320NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G0B5120NKU Leuven (Katholieke Universiteit Leuven) C16/18/007
6 · The paper itself

Abstract

Deficiency of adenosine deaminase 2 (DADA2) causes a complex phenotype of autoinflammation and immunodeficiency. Bone marrow failure is often refractory to treatment with tumour necrosis factor-alpha (TNF-alpha) inhibitors and additional treatment options are needed. However, the pathomechanisms underlying the disease remain incompletely understood. The aim of this study was to examine the viability and metabolic profile of ADA2-deficient cells and to characterise the activity of different cell death pathways to advance the mechanistic understanding of DADA2. By flow cytometry and western blot, we showed that ADA2

Identifiers

PMID41866403
PMCPMC13039166

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.